With a fundraising roadshow in the offing, Affitech A/S bolstered its pipeline by taking back in house a preclinical antivascular endothelial growth factor (VEGF) antibody development program it previously had licensed out to Peregrine Pharmaceuticals Inc. (BioWorld International)

With positive data from a Phase IIa trial in hand, Actelion AG plans to move directly into a Phase III morbidity/mortality trial of its first-in-class oral prostacyclin (PGI2) receptor agonist in pulmonary arterial hypertension (PAH) before year-end. (BioWorld International)